Bayer Maroc and Fondation Lalla Salma Join Forces for Oncology in Morocco

Cancer remains one of Morocco’s most pressing public health challenges. This summer, two major players in the country’s healthcare landscape decided to respond together. Bayer Maroc and Fondation Lalla Salma have signed a memorandum of understanding in Rabat, marking the launch of a new oncology partnership in Morocco. The agreement aims to improve access to therapeutic innovation, strengthen the training of healthcare professionals and enhance the overall care pathway for cancer patients, with a particular focus on prostate cancer.

A New Momentum for Cancer Care in Morocco

The signing took place in Rabat on 21 July 2026. Both institutions expressed a shared ambition: to build a stronger oncology ecosystem through innovation, professional training and a patient centred approach. The initiative fits within Morocco’s national health priorities, and it reflects a growing recognition that no single actor can address cancer care alone. Instead, coordinated action between public foundations and private health companies appears increasingly essential to close the gaps in prevention, diagnosis and treatment.

The Two Pillars of the Oncology Partnership in Morocco

This oncology partnership in Morocco rests on two main pillars. The first concerns access to therapeutic innovation in oncology, always within the applicable regulatory framework. The second focuses on developing the skills of healthcare professionals through continuous training, therapeutic education for patients, care pathway optimisation and the exchange of medical expertise. Together, these two axes are designed to translate scientific progress into tangible benefits for patients across the kingdom.

Prostate Cancer at the Heart of the Initiative

Among the areas of collaboration, prostate cancer has been identified as a particular priority. The partners intend to raise awareness, support more coordinated patient care and reinforce the knowledge of professionals working in this field. This focus responds to a real need, since prostate cancer continues to affect a significant number of Moroccan men, often diagnosed at a late stage due to limited screening habits.

Training Through the African School of Oncology

Beyond clinical care, the agreement also supports training initiatives through the African School of Oncology, a reference platform led by Fondation Lalla Salma. Through this framework, the two organisations aim to strengthen the competencies of healthcare professionals, spread best practices and promote excellence in cancer medicine, both in Morocco and, where relevant, across the African continent.

A Shared Voice on Collaboration

Anas Ziati, Director of the Pharma Division at Bayer Maroc, described the fight against cancer as one that “requires a collective approach that combines innovation, medical expertise and commitment.” His statement echoes the broader philosophy behind the agreement. Bayer brings decades of experience in oncology research and targeted therapies, while Fondation Lalla Salma contributes deep local expertise in prevention, screening and patient support built since its creation in 2005.

A Three Year Roadmap

The memorandum of understanding has been signed for a duration of three years, and the first joint initiatives are expected to begin in the third quarter of 2026. A joint committee has already been established to monitor progress, evaluate results and adjust the programme when necessary. This structured governance suggests that the partnership intends to move beyond a symbolic announcement and toward measurable outcomes for patients.

Toward a Stronger Oncology Ecosystem

As Morocco continues to face rising cancer rates, initiatives that combine institutional support, scientific innovation and professional training carry real significance. This oncology partnership in Morocco stands as one example of how collaboration between a global health company and a national foundation can shape a more resilient system of care. Above all, the coming months will show how these ambitions translate into concrete progress for patients across the country.